Rockville, MD /PRNewswire/ -- Some of the world's largest biopharmaceutical products, among the highest revenue generators in the pharmaceutical industry, may face competition from so-called "biosimilars," according to a new report from healthcare market research firm Kalorama Information. These close copies of biodrugs are coming to U.S. markets and the charge is lead by five companies. Kalorama details the efforts of these companies in its report: Biosimilars: Global Market, Trends and Competitor Analysis. In addition to these five household names: Sandoz, Pfizer, Eli Lilly, Merck and established biopharma player Biogen, Kalorama says there are other international companies that have products on the market or near market.
"There are many companies in this sector and we've documented that in our report, but these five have all really invested in biosimilar pipelines and are expected to make strides in the industry," said Melissa Elder, Kalorama analyst. "These companies are targeting the big drugs: Remicade, Rituxan, Lantus, Neulasta."
The report says early development efforts is strengthening. Biosimilars targeting Herceptin, Lucentis, Erbitux are up-and-coming. Nor is it just the case of small competitors developing drugs to compete with profitable brand names. The report says big pharma is taking a specialized interest in biosimilar development and commercialization. Major development agreements between niche biotech and big pharma is the trend - small biotech research combined with big pharma's commercialization and financial strengths.
The report lists many other smaller competitors who could make waves in the field. Among them are:
By no means is the biosimilar market limited to these ten companies. There are constant moves as companies develop products while protecting their own patents. Kalorama's report details the efforts of scores of companies. It also establishes market forecasts and predicts which biodrugs are under the heaviest competitive threat. The report is available at: https://www.kaloramainformation.com/Biosimilars-Global-Trends-Competitor-11277551/. It is also part of Kalorama Information's Knowledge Center.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.
SOURCE: Kalorama InformationCopyright 2017 PR Newswire. All Rights Reserved